Target intelligence / Profile preview

MAX gene-associated protein (MGA) mRNA (MGA)

Target
MGA
Molecular classification
Transcription factor, mRNA
01

Overview

MAX gene-associated protein (MGA) is a high-molecular-weight transcription factor that serves as a critical regulator within the MYC/MAX/MAD network and the non-canonical Polycomb Repressive Complex 1.6 (ncPRC1.6) (UniProt Q9UWI4). It contains both a T-box domain and a basic helix-loop-helix leucine zipper (bHLH-Zip) domain, enabling it to bind diverse DNA motifs and repress genes involved in the cell cycle and germ cell development (PubMed: 10591211). MGA is predominantly characterized as a tumor suppressor, and its genetic or epigenetic inactivation is a frequent driver in lung adenocarcinoma, colorectal cancer, and chronic lymphocytic leukemia (PubMed: 34238724, 30135580). Therapeutic strategies targeting MGA mRNA include the use of antisense oligonucleotides (ASOs) to inhibit oncogenic truncated isoforms or mRNA-based replacement therapies to restore full-length protein function in deficient cells (PubMed: 30135580). Recent research also suggests that MGA may be a target for enhancing immunotherapy in triple-negative breast cancer by modulating the tumor immune landscape (PNAS: 2406325121). Although no MGA-targeted drugs have reached the clinic, the target is of high interest for its ability to modulate the MYC pathway, which is traditionally considered undruggable.

Other names
MAD5MAX-associated proteinMGADMGA
02

Mechanism of action

Restoration of tumor suppressor function via mRNA delivery or inhibition of truncated isoforms via antisense oligonucleotides.

03

Biological functions

Regulation of transcriptionCell cycle regulationMYC pathway antagonismGerm cell development
04

Disease associations

Lung adenocarcinomaColorectal cancerTriple-negative breast cancerChronic lymphocytic leukemia
05

Safety considerations

Delivery of large mRNA transcriptsOff-target effects of RNA-based therapeuticsPotential for systemic toxicity
06

Biomarkers

MGA mutation statusMGA mRNA expression levelsIntronic polyadenylation (IPA) of MGA

Beyond the preview

Go deeper on MAX gene-associated protein (MGA) mRNA (MGA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAX gene-associated protein (MGA) mRNA (MGA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call